Phase I Study of Human Monoclonal Antibody 5B1 (MVT-5873) as Monotherapy and With Chemotherapy in Patients With Pancreatic Cancer or Other CA19-9 Positive Malignancies
Summary
04/19/2018 NOTE: Some sites may be enrolling into Group 2 alone. Please contact the site for verification.
The purpose of this phase I trial is to evaluate the safety and tolerability of HuMab-5B1 in patients with pancreatic cancer and other CA 19-9 positive cancers.
General Information
NCT#: NCT02672917
Study ID: MV-0715-CP-001.01
Trial Phase: Phase I
Trial Sponsor: BioNTech Research & Development, Inc.
Therapies Used in This Trial: MVT-5873